Crinetics Pharmaceuticals (CRNX) Non Operating Income (2017 - 2026)
Crinetics Pharmaceuticals' quarterly Non Operating Income came in at $12.5 million in Q1 2026, up 6273.89% year-on-year from $196630.3 in Q1 2025, and down 75.83% quarter-over-quarter from $51.9 million in Q4 2025.
Crinetics Pharmaceuticals has reported Non Operating Income for 10 years, with the latest figure at $12.5 million in Q1 2026.
- For the quarter ending Q1 2026, Non Operating Income rose 6273.89% year-over-year to $12.5 million; the trailing twelve-month figure through Mar 2026 stood at $64.4 million (up 91.32% YoY), and the FY2025 full-year result was $51.6 million, up 26.19% from the prior year.
- Non Operating Income for Q1 2026 stood at $12.5 million, down from $51.9 million in the prior quarter.
- The five-year high for Non Operating Income was $51.9 million in Q4 2025, with the low at -$203000.0 in Q1 2025.
- Average Non Operating Income over 5 years is $7.3 million, with a median of $2.0 million recorded in 2023.
- Year-over-year, Non Operating Income slumped 179.31% in 2022 and surged 20796.23% in 2024.
- Tracing CRNX's Non Operating Income over 5 years: stood at $2.6 million in 2022, then jumped by 425.38% to $13.5 million in 2023, then advanced by 5.0% to $14.2 million in 2024, then jumped by 266.53% to $51.9 million in 2025, then sank by 75.83% to $12.5 million in 2026.
- The last three Non Operating Income figures came in at $12.5 million (Q1 2026), $51.9 million (Q4 2025), and -$49000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 444,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 201.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -46.98 Mn |
| 10 | Crinetics Pharmaceuticals | 3.59 Bn | 3.59 Bn | 10.53 Mn | 12.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 12.53 Mn |
| Dec 31, 2025 | 51.86 Mn |
| Sep 30, 2025 | -49,000.00 |
| Jun 30, 2025 | 20,000.00 |
| Mar 31, 2025 | -203,000.00 |
| Dec 31, 2024 | 14.15 Mn |
| Sep 30, 2024 | 10.97 Mn |
| Jun 30, 2024 | 8.73 Mn |
| Mar 31, 2024 | 7.07 Mn |
| Dec 31, 2023 | 13.48 Mn |
| Sep 30, 2023 | -53,000.00 |
| Jun 30, 2023 | 2.02 Mn |
| Mar 31, 2023 | -55,000.00 |
| Dec 31, 2022 | 2.57 Mn |
| Sep 30, 2022 | 1.53 Mn |
| Jun 30, 2022 | -81,000.00 |
| Mar 31, 2022 | 210,000.00 |
| Dec 31, 2021 | -63,000.00 |
| Sep 30, 2021 | -68,000.00 |
| Jun 30, 2021 | -29,000.00 |
| Mar 31, 2021 | 17,000.00 |
| Dec 31, 2020 | 1.09 Mn |
| Sep 30, 2020 | 9,000.00 |
| Jun 30, 2020 | 178,000.00 |
| Mar 31, 2020 | 422,000.00 |
| Dec 31, 2019 | 665,000.00 |
| Sep 30, 2019 | -36,000.00 |
| Jun 30, 2019 | 918,000.00 |
| Mar 31, 2019 | 18,000.00 |
| Dec 31, 2018 | -812,000.00 |
| Sep 30, 2018 | 482,000.00 |
| Jun 30, 2018 | -36,000.00 |
| Mar 31, 2018 | -2,000.00 |
| Dec 31, 2017 | 66,000.00 |
| Sep 30, 2017 | -12,000.00 |
| Jun 30, 2017 | -5,000.00 |